福安药业
(300194)
| 流通市值：37.67亿 | | | 总市值：46.28亿 |
| 流通股本：9.68亿 | | | 总股本：11.90亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 839,297,466.77 | 407,493,108.61 | 1,738,291,062.31 | 1,315,372,998.73 |
| 营业收入 | 839,297,466.77 | 407,493,108.61 | 1,738,291,062.31 | 1,315,372,998.73 |
| 二、营业总成本 | 760,020,040.99 | 375,586,377.91 | 1,664,041,387.28 | 1,256,272,424.41 |
| 营业成本 | 507,024,771.01 | 242,140,742.5 | 1,095,715,330.73 | 832,940,616.62 |
| 税金及附加 | 15,279,038.68 | 8,067,419.06 | 26,256,350.96 | 19,625,240 |
| 销售费用 | 87,787,081.94 | 48,830,310.08 | 195,093,780.21 | 144,440,403.14 |
| 管理费用 | 98,492,654.97 | 47,953,125.1 | 219,631,250.11 | 157,883,677.54 |
| 研发费用 | 46,518,728.21 | 26,091,542.25 | 134,657,466.59 | 102,922,124.68 |
| 财务费用 | 4,917,766.18 | 2,503,238.92 | -7,312,791.32 | -1,539,637.57 |
| 其中:利息费用 | 7,597,825.9 | 3,931,573.18 | 22,153,601.56 | 17,096,399.02 |
| 其中:利息收入 | 4,318,929.28 | 2,248,838.28 | 29,899,881.3 | 18,758,005.77 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 346,712.32 | 230,027.39 | -1,861,434.87 | 483,917.81 |
| 加:投资收益 | 20,370,234.7 | 20,957,137.57 | 138,260,671.55 | 101,927,003.45 |
| 资产处置收益 | 10,303.05 | -3,075.22 | 266,139.3 | -42,703.27 |
| 资产减值损失(新) | -5,135,951.72 | -1,367,857.65 | -149,580,888.41 | -12,388,006.59 |
| 信用减值损失(新) | -411,218.75 | -709,108.59 | -6,593,326.91 | -5,172,835.27 |
| 其他收益 | 13,190,129.05 | 8,192,688.1 | 29,438,486.58 | 25,135,164.73 |
| 四、营业利润 | 107,647,634.43 | 59,206,542.3 | 84,179,322.27 | 169,043,115.18 |
| 加:营业外收入 | 437,549.87 | 84,932.15 | 3,233,729.92 | 1,109,205.2 |
| 减:营业外支出 | 2,160,036.54 | 379,659.41 | 4,169,476.03 | 2,269,832.89 |
| 五、利润总额 | 105,925,147.76 | 58,911,815.04 | 83,243,576.16 | 167,882,487.49 |
| 减:所得税费用 | 10,392,745.1 | 4,136,533.93 | 6,757,915.4 | 2,013,633.74 |
| 六、净利润 | 95,532,402.66 | 54,775,281.11 | 76,485,660.76 | 165,868,853.75 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 95,532,402.66 | 54,775,281.11 | 76,485,660.76 | 165,868,853.75 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 95,774,808.12 | 54,916,269.3 | 76,997,129.92 | 166,262,735.72 |
| 少数股东损益 | -242,405.46 | -140,988.19 | -511,469.16 | -393,881.97 |
| 扣除非经常损益后的净利润 | 86,436,552.47 | 48,649,638.11 | 59,644,999.66 | 148,497,322.24 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.08 | 0.05 | 0.06 | 0.14 |
| (二)稀释每股收益 | 0.08 | 0.05 | 0.06 | 0.14 |
| 八、其他综合收益 | -2,204,292.56 | 3,326,978.94 | -29,247,113.56 | -30,787,570.75 |
| 归属于母公司股东的其他综合收益 | -2,204,292.56 | 3,326,978.94 | -29,247,113.56 | -30,787,570.75 |
| 九、综合收益总额 | 93,328,110.1 | 58,102,260.05 | 47,238,547.2 | 135,081,283 |
| 归属于母公司股东的综合收益总额 | 93,570,515.56 | 58,243,248.24 | 47,750,016.36 | 135,475,164.97 |
| 归属于少数股东的综合收益总额 | -242,405.46 | -140,988.19 | -511,469.16 | -393,881.97 |
| 公告日期 | 2026-08-27 | 2026-04-27 | 2026-04-27 | 2025-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |